We demonstrate that co-treatment with bortezomib and PARP inhibitors leads to enhanced cytotoxicity in the absence of TRIM33, suggesting this combination could provide a therapeutic option for a subset of MM patients with loss of TRIM33. Here, TRIM33 is linked to Miyoshi myopathy.